Gastric cancer

Lancet

Volumn 362, Issue 9380, 2003, Pages 305-315

  Hohenberger, Peter ^a   Gretschel, Stephan ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CAGA PROTEIN; CELL ADHESION MOLECULE; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUORESCEIN; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G; INDIGO CARMINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; UVOMORULIN;

ABDOMINAL CANCER; ADVANCED CANCER; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DUODENUM ULCER; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOSCOPY; EUROPE; FOOD PRESERVATION; GASTRECTOMY; GENE MUTATION; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHATIC DRAINAGE; METASTASIS; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASTIC SURGERY; PRIORITY JOURNAL; SERODIAGNOSIS; SPLENECTOMY; STAINING; STOMACH CANCER; STOMACH ULCER; TOXICITY; TREATMENT INDICATION; TUMOR BIOPSY; UNITED STATES; WESTERN HEMISPHERE;

EID: 0043200978     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13975-X     Document Type: Conference Paper

References (117)

1. Allum W.H., Griffin S.M., Watson A., Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut. 50:(suppl 5):2002;1-23.
2. Wayman J., Forman D., Griffin S.M. Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes Control. 12:2001;943-949.
3. Terry M.B., Gaudet M.M., Gammon M.D. The epidemiology of gastric cancer. Semin Radiat Oncol. 12:2002;111-127.
4. WHO World Health Report. 1997;World Health Organization, Geneva.
5. National Cancer Institute. Surveillance, epidemiology, and end results: incidence, stomach cancer. http://www.seer.cancer.gov/faststats/html/inc_stomach.html (accessed July 12, 2002).
6. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA Cancer J Clin. 47:1997;5-27.
7. Dolan K., Sutton R., Walker S.J., Morris A.I., Campbell F., Williams E.M. New classification of of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 80:1999;834-842.
8. Kranenbarg E.K., van de Velde C.J. Gastric cancer in the elderly. Eur J Surg Oncol. 24:1998;384-390.
9. Anonymus. IARC Handbooks of Cancer Prevention, Vol 1 Geneva: International Agency for Research on Cancer, WHO; 1997.
10. Laurén P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Path Microbiol Imunol Scand. 64:1965;31-49.
11. La Vacchia C., Ferraroni M., D'Avanzo B., Decarli A., Franceschi S. Selected micronutrient intake and the risk of gastric cncer. Cancer Epidemiol Biomarkers. 3:1994;393-398.
12. Hansson LE, Nyren O, Bergstrom R, et al. Nutrients and gastric cancer risk: a population-based casecontrol study in Sweden. Int J Cancer 194; 57: 638-644.
13. Ogimoto I., Shibata A., Fukuda K. World Cancer Research Fund and American Institute of Cancer Research 1997 recommendations: applicability to digestive tract cancer in Japan. Cancer Causes Control. 11:2000;9-23.
14. Terry P., Lagergren J., Hansen H., Wolk A., Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev. 10:2001;365-369.
15. Meining A., Morgner A., Miehlke S., Bayerdörffer E., Stolte M. Atrophy-meta-plasia-dysplasia-carcinoma sequence in the stomach: a reality or merely a hypothesis? Best practice and research clinical gastroenterology. 15:2001;983-998.
16. La Vecchia C., Negri E., Franceschi S., Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer. 70:1992;50-55.
17. Hattori T. Development of adenocarcinomas in the stomach. Cancer. 57:1986;1528-1534.
18. Kirchner T., Muller S., Hattori T., et al. Metaplasia, intraepithelial neoplasia and early cancer of the stomach are related to dedifferentiated epithelial cells defined by cytokeratin-7 expression in gastritis. Virchows Arch. 439:2001;512-522.
19. Bamba M., Sugihara H., Kushima R., et al. Time-dependent expression of intestinal phenotype in signet ring cell carcinomas of the human stomach. Virchows Arch. 438:2001;49-56.
20. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1984;1311-1315.
21. Miyaji H., Azuma T., Ito S., et al. Helicobacter pylori infection occurs via close contact with infected individuals in early childhood. J Gastroenterol Hepatol. 15:2000;257-262.
22. Kikuchi S., Kurosawa M., Sakiyama T. Helicobacter pylori risk associated with sibship size and family history of gastric diseases in Japanese adults. Jpn J Cancer Res. 89:1998;1109-1112.
23. Kurosawa M., Kikuchi S., Inaba Y., Ishibashi T., Kobayashi F. Helicobacter pylori infection among Japanese children. J Gastroenterol Hepatol. 15:2000;1382-1385.
24. Krumbiegel P., Herbarth O., Fritz G., et al. Helicobacter pylori prevalence in Leipzig's 1998 school entries: methodology and first results. Int J Hyg Environ Health. 203:2000;11-16.
25. Parsonnet J., Vandersteen D., Goates J., Sibley R.K., Pritikin J., Chang Y. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 83:1991;640-643.
26. Nomura A., Stemmermann G.N., Chyou P.H., Kato I., Perez-Perez G.I., Blaser M.J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 325:1991;1132-1136.
27. Parsonnet J., Friedman G.D., Vandersteen D.P., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 325:1991;1127-1131.
28. Gallo N., Zambon C.-F., Navaglia F., et al. Helicobacter pylori infection in children and adults: a single pathogen but a different pathology. Helicobacter. 8:2003;21-28.
29. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:2001;784-789.
30. Hansson L.E., Nyren O., Hsing A.W., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 335:1996;242-249.
31. El-Omar EM, Carrington M, Chow W-H, et al. Interleukin-I polymorphisms associated with increased risk of gastric cancer. Nature 2002;??: 398-402.
32. Boren T., Falk P., Roth K.A., Larson G., Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 262:1993;1892-1895.
33. Chow W.H., Blaser M.J., Blot W.J., et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of oesophageal and gastric cardia adenocarcinoma. Cancer Res. 58:1998;588-590.
34. Zambon C.-F., Navaglia F., Basso D., Rugge M., Plebani M. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. J Clin Pathol. 56:2003;287-291.
35. Mahdavi J., Sonden B., Hurtig M., et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science. 297:2002;573-578.
36. Woodward M., Tunstall-Pedoe H., McColl K. Helicobacter pylori infection reduces systemic availability of dietary vitamin C. Eur J Gastroenterol Hepatol. 13:2001;233-237.
37. Sobala G.M., Schorah C.J., Shires S., et al. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut. 34:1993;1038-1041.
38. Correa P., Fontham E.T., Bravo J.C., et al. Chemoprevention of gastric dysplasia: randomised trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 92:2000;1881-1888.
39. Wu M.S., Shun C.T., Wang H.P., et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology. 112:1997;1457-1465.
40. Schlemper R.J., Itabashi M., Kato Y. Differences and diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet. 349:1997;1725-1729.
41. de Dombal F.T., Price A.B., Thompson H., et al. The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut. 31:1990;115-120.
42. Schlemper R.J., Riddell R.H., Kato Y. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 47:2000;251-255.
43. Hunerbein M., Ghadimi B.M., Haensch W., Schlag P.M. Transendoscopic ultrasound of esophageal and gastric cancer using miniaturized ultrasound catheter probes. Gastrointest Endosc. 48:1998;371-375.
44. Bhunchet E., Hatakawa H., Sakai Y., Shibata T. Fluorescein electronic endoscopy: a novel method for detection of early stage gastric cancer not evident to routine endoscopy. Gastrointest Endosc. 55:2002;562-571.
45. Shimoyama S., Yasuda H., Mafune K., Kaminishi M. Indications of a minimized scope of lymphadenectomy for submucosal gastric cancer. Ann Surg Oncol. 9:2002;625-631.
46. Gotoda T., Yanagisawa A., Sasako M., et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric.Cancer. 3:2000;219-225.
47. Hiki Y., Sakakibara Y., Mieno H., Shimao H., Kobayashi N., Katada N. Endoscopic treatment of gastric cancer. Surg Endosc. 5:1991;11-13.
48. Tani M., Takeshita K., Inoue H., Iwai T. Adequate endoscopic mucosal resection for early gastric cancer obtained from the dissecting microscopic features of the resected specimens. Gastric Cancer. 4:2001;122-131.
49. Ohgami M., Otani Y., Kumai K., Kubota T., Kim Y.I., Kitajima M. Curative laparoscopic surgery for early gastric cancer: five years experience. World J Surg. 23:1999;187-192.
50. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 5:2002;1-5.
51. Berndt H., Gütz H.J. Laparoskopie bei Magenkrebs. Z Gastroenterol. 3:1965;317-320.
52. Burke E.C., Karpeh M.S., Conlon K.C., Brennan M.F. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 225:1997;262-277.
53. Hunerbein M., Rau B., Hohenberger P., Schlag P.M. The role of staging laparoscopy for multimodal therapy of gastrointestinal cancer. Surg Endosc. 12:1998;921-925.
54. Feussner H., Kraemer S.J.M., Siewert J.R. Extended diagnostic laparoscopy in gastric cancer. Hohenberger P., Conlon K.C. Staging laparoscopy. 2002;83-95 Springer, Berlin.
55. Stell D.A., Carter C.R., Stewart I., Anderson J.R. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg. 83:1996;1260-1262.
56. D'Ugo D.M., Persiani R., Caracciolo F., Ronconi P., Coco C., Picciocchi A. Selection of locally advanced gastric carcinoma by preoperative staging laparoscopy. Surg Endosc. 11:1997;1159-1162.
57. Kocher H.M., Linklater K., Patel S., Ellul J.P. Epidemiological study of oesophageal and gastric cancer in southeast England. Br J Surg. 88:2001;1249-1257.
58. Corley D.A., Buffler P.A. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 30:2001;1415-1425.
59. Ye W., Chow W.H., Lagergren J., Yin L., Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 121:2001;1286-1293.
60. Corvalan A., Koriyama C., Akiba S., et al. Epstein-Barr virus in gastric carcinoma is associated with location in the cardia and with a diffuse histology: a study in one area of Chile. Int J Cancer. 94:2001;527-530.
61. Fukayama M., Chong J.M., Uozaki H. Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma. Curr Top Microbiol Immunol. 258:2001;91-102.
62. Aikou T., Natugoe S., Tenabe G., Baba M., Shimazu H. Lymph drainage originating from the lower esophagus and gastric cardia as measured by radioisotope uptake in the regional lymph nodes following lymphoscintigraphy. Lymphology. 20:1987;145-151.
63. de Manzoni G., Pedrazzani C., Di Leo A., et al. Metastases to the para-aortic lymph nodes in adenocarcinoma of the cardia. Eur J Surg. 167:2001;413-418.
64. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 85:1998;1457-1459.
65. Stein H.J., Feith M., Siewert J.R. Cancer of the esophagogastric junction. Surg Oncol. 9:2000;35-41.
66. de Manzoni G., Pedrazzani C., Pasini F., et al. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg. 73:2002;1035-1040.
67. Cuschieri A., Fayers P., Fielding J., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet. 347:1996;995-999.
68. Bottcher K., Siewert J.R., Roder J.D., Busch R., Hermanek P., Meyer H.J. [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group ('92)] in german. Chirurg. 65:1994;298-306.
69. Wanebo H.J., Kennedy B.J., Chmiel J., Steele G., Winchester D., Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 218:1993;583-592.
70. Akoh J.A., Macintyre I.M. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg. 79:1992;293-299.
71. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 79:1999;1522-1530.
72. Siewert J.R., Bottcher K., Stein H.J., Roder J.D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 228:1998;449-461.
73. Ajani J.A., Mansfield P.F., Lynch P.M., et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 17:1999;2403-2411.
74. Fink U., Ott K., Dittler H.J., et al. Neoadjuvant cisplatinum, leucovorin and fluorouracil (PLF) in adequately staged patients with locally advanced gastric carcinoma. Proc Am Soc Clin Oncol. 18:1999;272.
75. Kang Y., Choi D., Im Y., et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc Am Soc Clin Oncol. 15:1996;215.
76. Songun I., Keizer H.J., Hermans J., et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 35:1999;558-562.
77. Skoropad V.Y., Berdov B.A., Mardynski Y.S., Titova L.N. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol. 26:2000;773-779.
78. Zhang Z.X., Gu X.Z., Yin W.B., Huang G.J., Zhang D.W., Zhang R.G. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys. 42:1998;929-934.
79. Melcher A.A., Mort D., Maughan T.S. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer. 74:1996;1651-1654.
80. Cascinu S., Labianca R., Alessandroni P., et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol. 15:1997;3313-3319.
81. Allum W., Cunningham D., Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: randomsied controlled trial (the MAGIC trial). Proc Am Soc Clin Oncol. 22:2003;A998.
82. Bozzetti F., Marubini E., Bonfanti G., et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 226:1997;613-620.
83. Inoue Y. About the lymphatic system of the stomach, duodenum, pancreas and diaphragm (in Japanese). Acta Anat Nipponica 1936; 35-117.
84. Siewert J.R., Kestlmeier R., Busch R., et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases [see comments]. Br J Surg. 83:1996;1144-1147.
85. Bonenkamp J.J., Hermans J., Sasako M., van-de-Velde C.J. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med. 340:1999;908-914.
86. Bonenkamp J.J., Songun I., Hermans J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients [see comments]. Lancet. 345:1995;745-748.
87. Dent D.M., Madden M.V., Price S.K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 75:1988;110-112.
88. Wolf H.M., Eibl M.M., Georgi E., et al. Long-term decrease of CD4+CD45RA+ T cells and impaired primary immune response after post-traumatic splenectomy. Br J Haematol. 107:1999;55-68.
89. Kitamura K., Nishida S., Ichikawa D., et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg. 86:1999;119-122.
90. Kampschoer G.H., Maruyama K., van de Velde C.J., Sasako M., Kinoshita T., Okabayashi K. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg. 76:1989;905-908.
91. Bollschweiler E., Boettcher K., Hoelscher A.H., et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg. 79:1992;156-160.
92. Guadagni S., de-Manzoni G., Catarci M., et al. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg. 24:2000;1550-1558.
93. Weinberg J.G.E.M. Identification of regional lymph nodes by means of a vital staining dye during surgery of gastric cancer. Surg Gynecol Obstet. 90:1950;561-567.
94. Catarci M., Guadagni S., Zaraca F., et al. Prospective randomized evaluation of preoperative endoscopic vital staining using CH-40 for lymph node dissection in gastric cancer [see comments]. Ann Surg Oncol. 5:1998;580-584.
95. Takahashi T., Sawai K., Hagiwara A., Takahashi S., Seiki K., Tokuda H. Type-oriented therapy for gastric cancer effective for lymph node metastasis: management of lymph node metastasis using activated carbon particles adsorbing an anticancer agent. Semin Surg Oncol. 7:1991;378-383.
96. Kitagawa Y., Fujii H., Mukai M., Kubota T., Otani Y., Kitajima M. Radio-guided sentinel node detection for gastric cancer. Br J Surg. 89:2002;604-608.
97. Ichikura T., Morita D., Uchida T., et al. Sentinel node concept in gastric carcinoma. World J Surg. 26:2002;318-322.
98. Hiratsuka M., Miyashiro I., Ishikawa O., et al. Application of sentinel node biopsy to gastric cancer surgery. Surgery. 129:2001;335-340.
99. Troidl H., Kusche J., Vestweber K.H., Eypasch E., Maul U. Pouch versus esophagojejunostomy after total gastrectomy: a randomized clinical trial. World J Surg. 11:1987;699-712.
100. Schwarz A., Buchler M., Usinger K., et al. Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg. 20:1996;60-66.
101. Visick A.H. Measured radical gastrectomy. Lancet. 2:1948;505.
102. Spitzer W.O., Dobson A.J., Hall J., et al. Measuring the quality of olife of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 34:1981;585.
103. Fuchs K.H., Thiede A., Engemann R., Deltz E., Stremme O., Hamelmann H. Reconstruction of the food passage after total gastrectomy: randomized trial. World J Surg. 19:1995;698-705.
104. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 35:1999;1059-1064.
105. Rosen H.R., Jatzko G., Repse S., et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol. 16:1998;2733-2738.
106. Wansik Y., Whang I., Suh I., et al. Prospective rndomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 228:1998;347-354.
107. MacDonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., Martenson J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 10:2001;725-730.
108. Hundahl S.A., Macdonald J.S., Benedetti J., Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 9:2002;278-286.
109. Schwartz R.E. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol. 19:2001;1879-1884.
110. Mattano L.A. Jr, Moss T.J., Emerson S.G. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res. 52:1992;4701-4705.
111. Hosch S., Kraus J., Scheunemann P., et al. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. 60:2000;6836-6840.
112. Molino A., Colombatti M., Bonetti F., et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer. 67:1991;1033-1036.
113. Putz E., Witter K., Offner S., et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 59:1999;241-248.
114. Allgayer H., Heiss M.M., Riesenberg R., et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 57:1997;1394-1399.
115. Choi H.J., Kim Y.K., Kim Y.H., Kim S.S., Hong S.H. Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma. Ann Surg Oncol. 9:2002;13-19.
116. Miyazono F., Natsugoe S., Takao S., et al. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg. 233:2001;189-194.
117. Jauch K.W., Heiss M.M., Gruetzner U., et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol. 14:1996;1810-1817.